rTMS for Apathy Clinical Trial
NCT05561205
Summary
Apathy is a common, early, and disabling symptom in dementias and mild behavioural impairment such as Alzheimer's disease (AD) and is characterized by lack of interest and enthusiasm. Both repetitive transcranial magnetic stimulation (rTMS), a form of non-invasive brain stimulation, and methylphenidate, a medication, have been shown to improve apathy. This pilot study will investigate rTMS as a treatment for apathy in neurocognitive disorders and mild behavioural impairment in individuals receiving methylphenidate and individuals not receiving medication for apathy.
Eligibility
Inclusion Criteria: * mild or major neurocognitive disorder OR mild behavioural impairment * Apathy for at least 4 weeks * Stable dose of medication (\>4 weeks) that may affect cognition or behaviour * Care partner who spends at least 10 hours a week with the subject Exclusion Criteria: * Current major depressive episode * Agitation, delusions, hallucination * Medical contraindications to rTMS * Currently taking an amphetamine product * Central nervous system abnormalities, Tourette's syndrome, or motor tics * Current participation in another clinical trial
Conditions7
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
NCT05561205